| Expression pattern: |
DN |
| Associated gene: |
GJB6, TMZ, HA-CS NPs |
| Associated microRNA: |
miR-890 |
| Biological function: |
Inhibits glioma cell viability, migration, invasion and tumor growth, promotes apoptosis, and enhances the anti-tumor effect of TMZ when co-delivered by HA-CS nanoparticles. |
| Molecular mechanism: |
circCDR1 acts as a ceRNA that sponges miR-890 to increase GJB6 expression; HA-CS nanoparticles co-deliver circCDR1 and TMZ into glioma cells to enhance anti-tumor effects. |
| Biological pathway or process: |
ceRNA regulation (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); apoptosis (promotes); drug resistance (other) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Bioinformatics Analysis; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; CCK8; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis |
| Clinical significance: |
Low circCDR1 expression was associated with poor prognosis of glioma patients; circCDR1 may be a potential therapeutic target and nanoparticle-delivered circCDR1/TMZ may provide a new treatment approach. |
| Description: |
circCDR1 is down-regulated in glioma tissues and cells, and low circCDR1 expression is associated with poorer overall survival. Functionally, circCDR1 suppresses glioma progression by sponging miR-890 and up-regulating GJB6, thereby inhibiting proliferation, migration and invasion while promoting apoptosis. HA-CS nanoparticles co-delivering circCDR1 and TMZ enhanced anti-glioma effects in vitro and in a LN229 xenograft model. |
| Confidence score: |
0.8486 |